Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) provided a corporate update on its barium and iodine contrast media projects, outlining a strategic roadmap to address supply chain vulnerabilities in the diagnostic imaging sector. The global contrast media market is projected to grow from US$6.77 billion in 2024 to US$13.86 billion by 2033, according to Research Contrast. With barite classified as a critical mineral by the U.S. Geological Survey, Voyageur's strategy focuses on creating a secure, vertically integrated supply chain for both barium and iodine active pharmaceutical ingredients, covering the entire value chain from mineral discovery to finished product manufacturing.
The company is advancing two bankable feasibility studies (BFS): the Voyageur Radiology Iodine & Barium Drug Manufacturing Project and the Bayer Iodine Project. The Frances Creek barium contrast project, now in the BFS phase, hosts an indicated and inferred mineral resource of 132,000 tonnes of pharmaceutical grade barium sulfate, with an average grade of 98.8% BaSO4, exceeding the Pharmaceutical Grade threshold of 97.5%. Voyageur has completed product development for five Health Canada approved barium products with Alberta Veterinary Laboratories and generated approximately C$32,000 in initial sales, providing commercial validation. The company expects to deliver the FC barium BFS in the second half of 2026, following geotechnical drilling at the FC quarry site.
On the regulatory front, Voyageur has commenced the FDA approval process for barium products via the 505(b)(2) pathway, with submission documents drafted and formal process initiated in February 2026. The FDA review process is anticipated to take approximately one year, with product testing projected at six to seven months, potentially enabling U.S. barium market entry as soon as mid-2027 to late-2027. The company plans to advance a generic iodine FDA license in the second half of 2026.
For iodine, Voyageur is independently advancing a prefeasibility study for iodine contrast media drug production, integrating the Mueller iodine extraction process with the Streamline iodine drug manufacturing platform. This approach targets 35 million doses per year of iodine contrast drug production using iodine-rich brine from U.S. oil and gas operations. The company is also anchored by the Bayer Iodine Project, where Bayer may provide capital financing under an offtake-linked production financing arrangement, subject to successful completion of the BFS. All intellectual property developed in connection with the project will remain exclusively owned by Voyageur.
Voyageur is engaging a global engineering company to complete the final two BFS: one for the radiology drug manufacturing project and one for the Bayer Iodine project. Upon completion, the company will have finalized economics and plant design for vertically integrated production of barium and iodine contrast media drugs, positioning it as the only vertically integrated radiology drug company. Voyageur is actively reviewing financial options to fund CAPEX, targeting construction to commence in 2027. For more information, visit https://voyageurpharmaceuticals.ca.
